AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12527500 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulin (Pentaglobin(R)) preparation (1,300 ml immunoglobulin, equivalent to 65 g protein)
Number of subjects: 41
Study 12527500 — intervention group
Group type: COMPARATOR
Intervention: Routine antibiotic prophylaxis plus placebo
Number of subjects: 41
Study 12527500 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulin (Pentaglobin(R)) preparation
Number of subjects: 41
Study 9703374 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg potassium iodide daily for 4 months
Number of subjects: 83
Study 9703374 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iodine treatment)
Number of subjects: 83
Study 9703374 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-treated group
Number of subjects: 83
Study 9703374 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 7808903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal combined with observational and physical techniques
Number of subjects: 40
Study 7808903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal
Number of subjects: 40
Study 2506603 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg adinazolam mesylate
Number of subjects: 15
Study 2506603 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg adinazolam mesylate
Number of subjects: 15
Study 2506603 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg adinazolam mesylate
Number of subjects: 15
Study 2506603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1090967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 57
Study 1090967 — intervention group
Group type: COMPARATOR
Intervention: Nurses' guesses
Number of subjects: 57
Study 1090967 — intervention group
Group type: COMPARATOR
Intervention: Patients' relatives' guesses
Number of subjects: 57
Study 31123181 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfiltration (iGFR levels ≥140 ml/min per 1.73 m2)
Number of subjects: 446
Study 31123181 — intervention group
Group type: COMPARATOR
Intervention: Baseline GFR <140 ml/min per 1.73 m2
Number of subjects: 446
Study 27539079 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPP (PolySoft mesh)
Number of subjects: 238
Study 27539079 — intervention group
Group type: COMPARATOR
Intervention: ProGrip (self-fixing semi-resorbable mesh)
Number of subjects: 238
Study 25504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexmedetomidine (10 µg)
Number of subjects: 84
Study 25504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus clonidine (75 µg)
Number of subjects: 84
Study 25504002 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 84
Study 25504002 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine plus fentanyl (15.0 µg)
Number of subjects: 84
Study 23831069 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration (20 mL of 0.25%)
Number of subjects: 121
Study 23831069 — intervention group
Group type: COMPARATOR
Intervention: No bupivacaine infiltration (control group)
Number of subjects: 121
Study 23831069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL
Number of subjects: 121
Study 23831069 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL
Number of subjects: 121
Study 22842775 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated assistance (AA, n = 36)
Number of subjects: 100
Study 22842775 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated assistance + calls (AAC, n = 50)
Number of subjects: 100
Study 22842775 — intervention group
Group type: COMPARATOR
Intervention: Observation-only group (OO, n = 14)
Number of subjects: 100
Study 19200277 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanol containing food products for three months
Number of subjects: 84
Study 19200277 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 18089864 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (six weekly 2-hour sessions)
Number of subjects: 262
Study 18089864 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 262
Study 15323591 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone ER (20 mg to 80 mg daily)
Number of subjects: 133
Study 15323591 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone ER
Number of subjects: 133
Study 15323591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 16208074 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving nursing counseling and walking exercise (12 weeks)
Number of subjects: 59
Study 16208074 — intervention group
Group type: COMPARATOR
Intervention: Control group (same treatment as before)
Number of subjects: 59
Study 10702886 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate 200 mg
Number of subjects: 22
Study 10702886 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol 100 mg
Number of subjects: 22
Study 10702886 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol and its metabolites (OPC‐13015 and OPC‐13213)
Number of subjects: 22
Study 8734724 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance load of 5 cm H2O/L/sec
Number of subjects: 15
Study 8734724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed flow and breathing rates
Number of subjects: 15
Study 8734724 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal breathing, fixed flow rate, fixed breathing rate, and fixed flow and breathing rate
Number of subjects: 15
Study 2009147 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril
Number of subjects: 1008
Study 6218350 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lauryl sulfate (A-137) alcoholic solution, applied topically 3 times daily for 8 weeks.
Number of subjects: 36
Study 6218350 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control group), applied topically 3 times daily for 8 weeks.
Number of subjects: 36
Study 31647093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies using data from related individuals (sibling pairs or parent-offspring trios)
Number of subjects: 0
Study 31647093 — intervention group
Group type: COMPARATOR
Intervention: Mendelian randomization studies using data from unrelated individuals
Number of subjects: 0
Study 29027667 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 20
Study 29027667 — intervention group
Group type: COMPARATOR
Intervention: CD4+ CD57+ PD-1- T cells
Number of subjects: 20
Study 26403160 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) plus peginterferon alfa-2b and ribavirin for 12 weeks then peginterferon alfa-2b and ribavirin for 12 weeks
Number of subjects: 294
Study 26403160 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) plus peginterferon alfa-2b and ribavirin for 24 weeks
Number of subjects: 294
Study 26403160 — intervention group
Group type: COMPARATOR
Intervention: Control: peginterferon alfa-2b and ribavirin alone for 48 weeks
Number of subjects: 294
Study 23845385 — intervention group
Group type: EXPERIMENTAL
Intervention: LiTMUS trial participants
Number of subjects: 0
Study 23845385 — intervention group
Group type: COMPARATOR
Intervention: Previous bipolar disorder efficacy studies
Number of subjects: 0
Study 22516981 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized or fixed‐dose GH treatment
Number of subjects: 99
Study 20099955 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about the most stressful or traumatic gay-related event for 20 min a day for 3 consecutive days
Number of subjects: 77
Study 20099955 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing about a neutral topic for 20 min a day for 3 consecutive days
Number of subjects: 77
Study 18474155 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 30
Study 18474155 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 30
Study 15631558 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 142
Study 15631558 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study 12491045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive polychemotherapy given both pre- and post-surgery for Ewing tumors
Number of subjects: 0
Study 12491045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive polychemotherapy given both pre- and post-surgery for osteosarcoma
Number of subjects: 0
Study 12491045 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy for chondrosarcomas
Number of subjects: 0
Study 10636472 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 6
Study 10636472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10636472 — intervention group
Group type: COMPARATOR
Intervention: 10 mg flumazenil
Number of subjects: 6
Study 9345400 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b, 8 MIU given subcutaneously every other day for 3 years
Number of subjects: 0
Study 9345400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31107394 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation participation
Number of subjects: 8
Study 31107394 — intervention group
Group type: EXPERIMENTAL
Intervention: VR observation
Number of subjects: 8
Study 31107394 — intervention group
Group type: COMPARATOR
Intervention: Television observation
Number of subjects: 8
Study 31073124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 µg/vilanterol 25 µg (FF/VI)
Number of subjects: 400
Study 31073124 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 400
Study 28441699 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Folic Acid (10 mg enalapril and 0.8 mg folic acid)
Number of subjects: 20702
Study 28441699 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone (10 mg enalapril)
Number of subjects: 20702
Study 26520926 — intervention group
Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen (darunavir 800 mg once per day + ritonavir 100 mg once per day + raltegravir 400 mg twice per day)
Number of subjects: 146
Study 26520926 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (darunavir 800 mg once per day + ritonavir 100 mg once per day + tenofovir 245 mg once per day + emtricitabine 200 mg once per day)
Number of subjects: 146
Study 26520926 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 146
Study 26520926 — intervention group
Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen
Number of subjects: 146
Study 26520926 — intervention group
Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen and Standard regimen
Number of subjects: 146
Study 23885523 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine diagnosis
Number of subjects: 414
Study 21443993 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA) for self-monitoring
Number of subjects: 192
Study 21443993 — intervention group
Group type: COMPARATOR
Intervention: Paper record for self-monitoring
Number of subjects: 192
Study 21443993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PDA and Paper record)
Number of subjects: 192
Study 19801029 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin (50 U/kg, max 5,000 U)
Number of subjects: 500
Study 19801029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial heparin (50 U/kg, max 5,000 U)
Number of subjects: 500
Study 16891758 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily walking for 4 weeks
Number of subjects: 0
Study 16891758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15577595 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid gastric emptying parameters (T1/2, TRE)
Number of subjects: 476
Study 15577595 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid gastric emptying parameter (Tlag)
Number of subjects: 476
Study 15577595 — intervention group
Group type: COMPARATOR
Intervention: Liquid gastric emptying parameters
Number of subjects: 476
Study 15577595 — intervention group
Group type: COMPARATOR
Intervention: Gastric emptying (GE) classification
Number of subjects: 476
Study 15577595 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between solid T1/2 and TRE
Number of subjects: 476
Study 15577595 — intervention group
Group type: EXPERIMENTAL
Intervention: GE parameters in patients with normal results
Number of subjects: 476
Study 11740297 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate and glucose (CR-CHO)
Number of subjects: 19
Study 11740297 — intervention group
Group type: COMPARATOR
Intervention: Protein and glucose (PRO-CHO)
Number of subjects: 19
Study 11740297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CR-CHO and PRO-CHO
Number of subjects: 19
Study 9005908 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced cementing technique (canal irrigation, brushing and drying with gauze, canal plugging, low viscosity cement pressurization with a delivery system)
Number of subjects: 16
Study 9005908 — intervention group
Group type: COMPARATOR
Intervention: Conventional cementing technique (doughy cement manually inserted and packed)
Number of subjects: 16
Study 7901979 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation during follow-up treatment
Number of subjects: 0
Study 7901979 — intervention group
Group type: COMPARATOR
Intervention: Open knee joint operations and arthroscopically controlled reconstruction operations
Number of subjects: 0
Study 7901979 — intervention group
Group type: COMPARATOR
Intervention: Injury alone
Number of subjects: 0
Study 7901979 — intervention group
Group type: COMPARATOR
Intervention: Follow-up treatment
Number of subjects: 0
Study 3425350 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline (mean plasma concentration 3 mg l‐1)
Number of subjects: 6
Study 3425350 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (mean plasma concentration 9 mg l‐1)
Number of subjects: 6
Study 3425350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31112053 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-Friendly Hospital Initiative compliance assessment
Number of subjects: 180
Study 30219823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (LDMTX) 5-15 mg/week
Number of subjects: 176
Study 30219823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plus folic acid)
Number of subjects: 176
Study 30219823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (LDMTX)
Number of subjects: 176
Study 30219823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 27630212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671
Study 27630212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study 27630212 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4i therapy (including sitagliptin)
Number of subjects: 14671
Study 25371077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed + Carboplatin (Pem+Cb)
Number of subjects: 361
Study 25371077 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel + Carboplatin + Bevacizumab (Pac+Cb+Bev)
Number of subjects: 361
Study 23061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg intravenous every 12 hours)
Number of subjects: 165
Study 23061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg intravenous every 6 hours)
Number of subjects: 165
Study 23061387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 23061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (high-dose: 80 mg bolus plus 8 mg/hr infusion for 3 days, then 40 mg intravenous every 12 hours for 7 days)
Number of subjects: 165
Study 23061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 165
Study 23061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 165
Study 21216122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-cha (Rubus suavissimus) 400mg (3 capsules/day) for 4 weeks
Number of subjects: 89
Study 21216122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 capsules/day) for 4 weeks
Number of subjects: 89
Study 19893562 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic and analgesics
Number of subjects: 198
Study 19893562 — intervention group
Group type: COMPARATOR
Intervention: Post-operative ECG monitoring
Number of subjects: 198
Study 16843192 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 300
Study 16843192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg
Number of subjects: 300
Study 16843192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Simvastatin 20 mg + Fenofibrate 160 mg)
Number of subjects: 300
Study 16843192 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 300
Study 12576122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milkshake
Number of subjects: 192
Study 12576122 — intervention group
Group type: COMPARATOR
Intervention: Low-fat milkshake
Number of subjects: 192
Study 11164436 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon44 genotype in hypercholesterolemic patients
Number of subjects: 239
Study 11164436 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon32 genotype in hypercholesterolemic patients
Number of subjects: 239
Study 11164436 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon22 genotype in hypertriglyceridemic patients
Number of subjects: 239
Study 11164436 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon42 genotype in hypertriglyceridemic patients
Number of subjects: 239
Study 11164436 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon43 genotype in hypertriglyceridemic patients
Number of subjects: 239
Study 11164436 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon44 genotype in hypertriglyceridemic patients
Number of subjects: 239
Study 9359441 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial monitoring by cardiotocography and measurement of amniotic fluid index
Number of subjects: 0
Study 9359441 — intervention group
Group type: COMPARATOR
Intervention: Immediate induction
Number of subjects: 0
Study 8267390 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant perioperative portal infusion with Fluorouracil and Mitomycin
Number of subjects: 533
Study 8267390 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 533
Study 3512326 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir cream applied 4 times per day for 16 weeks
Number of subjects: 23
Study 3512326 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied 4 times per day for 16 weeks
Number of subjects: 23
Study 30888235 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial canal wall preserved tympanomastoidectomy (PCM)
Number of subjects: 39
Study 30888235 — intervention group
Group type: COMPARATOR
Intervention: Canal wall down tympanomastoidectomy (CWD)
Number of subjects: 39
Study 28815419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily for the first week, then 100 mg for the following seven weeks)
Number of subjects: 56
Study 28815419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25154706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular typhoid vaccination
Number of subjects: 16
Study 25154706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular saline)
Number of subjects: 16
Study 23758145 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care
Number of subjects: 20
Study 23758145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management and/or in-depth interviews
Number of subjects: 20
Study 23758145 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stressors
Number of subjects: 20
Study 21252013 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous skeletal myoblast therapy
Number of subjects: 40
Study 21252013 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment
Number of subjects: 40
Study 19368899 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized auditory training (50 hours over 10 weeks)
Number of subjects: 56
Study 19368899 — intervention group
Group type: COMPARATOR
Intervention: Computer game control condition
Number of subjects: 56
Study 17357282 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal ultraviolet light-exposure (UVLE)
Number of subjects: 103
Study 17357282 — intervention group
Group type: EXPERIMENTAL
Intervention: Biospecific hemosorption (BSS)
Number of subjects: 103
Study 17357282 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS plus UVLE
Number of subjects: 103
Study 17357282 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with antibiotics
Number of subjects: 103
Study 17357282 — intervention group
Group type: EXPERIMENTAL
Intervention: All EED methods (UVLE and BSS)
Number of subjects: 103
Study 14731308 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined monoamine depletion (CMD; via tryptophan, tyrosine and phenylalanine depletion)
Number of subjects: 20
Study 14731308 — intervention group
Group type: COMPARATOR
Intervention: Balanced control condition (B)
Number of subjects: 20
Study 11480646 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations (4-META-based resin)
Number of subjects: 60
Study 11480646 — intervention group
Group type: COMPARATOR
Intervention: Pin-retained amalgam restorations (self-threading pins)
Number of subjects: 60
Study 11480646 — intervention group
Group type: COMPARATOR
Intervention: Both groups (bonded and pin-retained)
Number of subjects: 60
Study 10194995 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 76
Study 10194995 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 8064049 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical periodontal therapy
Number of subjects: 11
Study 8064049 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical periodontal therapy
Number of subjects: 11